Jinhai International Group Holdings Limited (2225) AI Stock Analysis

• Market Cap: HK$6.24B
• Dividend Yield: N/A
• Average Volume (3M): 8.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -33.94%
• EPS Growth: -119.13%
• Country: HK
• Employees: 488
• Sector: Industrials
• Sector Strength: 72
• Industry: Staffing & Employment Services
• EPS (TTM): -0.01
• Shares Outstanding: 5,290,000,000
• 10 Day Avg. Volume: 11,309,500
• 30 Day Avg. Volume: 8,014,966
• PEG Ratio: -2.40
• Price to Book (P/B): 54.28
• Price to Sales (P/S): 34.36
• P/FCF Ratio: -404.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: HK$1.00 ▼(-2.91% Downside)

The overall stock score is primarily influenced by the company's financial performance, which faces significant challenges with declining revenue and profitability. Technical analysis provides mixed signals, with slight positive momentum but no clear trend. Valuation is a concern due to the negative P/E ratio and lack of dividend yield, indicating limited attractiveness.

Jinhai International Group Holdings Limited Business Overview & Revenue Model

Company Description

Jinhai Medical Technology Ltd. provides manpower outsourcing and ancillary services. It offers services to the building and construction contractors also provides dormitory, warehousing, cleaning, and building maintenance services. The company was founded in 2006 and is headquartered in China.

How the Company Makes Money

Jinhai International Group Holdings Limited generates revenue through multiple streams. Its core revenue comes from the manufacturing and sale of consumer goods, particularly electronics and textiles, which are distributed both domestically and internationally. The company also earns income from its trading activities, where it acts as an intermediary between manufacturers and retailers. Additionally, Jinhai International has revenue from property investment and development, leveraging its real estate assets to generate rental income and profits from property sales. Strategic partnerships with suppliers and distributors enhance its operational efficiency and market reach, while its logistics and warehousing services further contribute to its earnings by optimizing supply chain management.

Jinhai International Group Holdings Limited Financial Statement Overview

Summary

Jinhai International Group Holdings Limited faces significant financial challenges, with declining revenue and profitability, alongside cash flow constraints. While leverage is manageable, the company's ability to generate positive returns and cash flow is a concern, requiring strategic adjustments to improve financial health.

Income Statement

The company has experienced a decline in revenue growth, with a significant decrease in net income, resulting in negative net profit margins. The gross profit margin has also decreased, indicating pressure on profitability. Negative EBIT and EBITDA margins further highlight operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the equity ratio has decreased, suggesting a reduction in equity relative to assets. Return on equity is negative due to net losses, which is a concern for investors.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating cash management issues. The operating cash flow to net income ratio is negative, reflecting challenges in converting earnings to cash. Free cash flow growth is also negative, pointing to potential liquidity constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.83M	50.24M	45.64M	22.28M	21.90M	22.47M
Gross Profit	6.14M	11.48M	12.03M	10.12M	7.73M	8.85M
EBITDA	-20.18M	-16.82M	1.11M	5.25M	5.44M	2.15M
Net Income	-22.18M	-17.96M	-3.14M	468.00K	-246.21K	1.26M
Balance Sheet
Total Assets	50.15M	58.87M	62.22M	40.27M	33.77M	39.41M
Cash, Cash Equivalents and Short-Term Investments	6.97M	14.93M	26.76M	23.95M	25.91M	27.39M
Total Debt	14.67M	14.52M	10.08M	4.45M	1.87M	5.50M
Total Liabilities	22.38M	26.09M	24.73M	15.68M	9.75M	13.92M
Stockholders Equity	27.36M	31.81M	37.47M	24.37M	24.28M	25.49M
Cash Flow
Free Cash Flow	-4.86M	-4.26M	-3.15M	3.06M	2.73M	7.25M
Operating Cash Flow	-4.10M	-3.25M	-1.91M	4.24M	3.34M	7.38M
Investing Cash Flow	-1.63M	-9.22M	-6.51M	-1.15M	-2.64M	-6.04M
Financing Cash Flow	3.11M	2.93M	13.62M	-3.72M	-4.81M	-4.15M

Jinhai International Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Neutral. The current price of 1.03 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.09, and below the 200-day MA of 1.27, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 51.49 is Neutral, neither overbought nor oversold. The STOCH value of 27.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2225.

Jinhai International Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2180	73 Outperform	HK$1.04B	6.82	11.29%	37.90%	17.49%	9.67%
6100	72 Outperform	HK$1.83B	11.86	―	―	-10.48%	30250.00%
8462	66 Neutral	HK$53.40M	5.30	7.43%	―	-11.47%	5.00%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
8031	53 Neutral	HK$54.40M	-5.58	―	―	―	―
2225	51 Neutral	HK$6.24B	―	-67.70%	―	-33.94%	-119.13%
6919	46 Neutral	HK$677.98M	―	-4.09%	2.03%	14.29%	-200.37%

Jinhai International Group Holdings Limited Corporate Events

Jinhai Medical Technology Partners with Medtronic Changzhou for Spinal Endoscopy Advancement

Jinhai Medical Technology Limited announced a strategic cooperation framework agreement with Medtronic Changzhou to promote real-time navigation and tracking spinal endoscope techniques in the PRC. This collaboration aims to develop advanced integrated solutions for spinal endoscopy, facilitate academic exchanges, and support clinical demonstrations and training. The agreement, initially set for one year, can be renewed, and formal agreements will be established as conditions mature, potentially enhancing Jinhai’s market position in the medical technology sector.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical to Launch Innovative Spinal Surgery Technique at CIIE

Jinhai Medical Technology Limited, a subsidiary of Jinhai International Group Holdings, is preparing to participate in the Eighth China International Import Expo in Shanghai. At the event, Jinhai Medical, in collaboration with Medtronic China, will introduce a new navigated spinal endoscope technique aimed at enhancing precision and efficiency in spinal surgeries. This development is expected to significantly impact the field of spinal surgery by facilitating broader clinical applications and reducing the learning curve for clinicians.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Announces Key Leadership Changes

Jinhai Medical Technology Limited has announced a change in its company secretary, authorised representative, and process agent roles. Ms. Cheng Yuen has resigned from these positions, effective September 29, 2025, and Mr. Wong Man Yiu has been appointed to fill the vacancies. Mr. Wong, who previously served in similar roles within the company, brings extensive experience in company secretarial practices and regulatory requirements. This change is expected to maintain the company’s compliance and operational efficiency.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Reports Decline in 1H2025 Financial Results

Jinhai Medical Technology Limited reported a significant decline in its financial performance for the first half of 2025, with revenue dropping from S$25,937,000 in 2024 to S$14,529,000 in 2025. The company faced a loss before tax of S$10,722,000, compared to a loss of S$5,941,000 in the same period last year, indicating challenges in maintaining profitability. This downturn in financial results could impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Issues Profit Warning Amid Increased Losses

Jinhai Medical Technology Limited has issued a profit warning, anticipating a significant increase in net loss for the first half of 2025, compared to the same period in 2024. The expected loss of approximately S$10.8 million is primarily due to a decrease in gross profit, attributed to reduced revenue from its core business operations. This announcement may impact stakeholders’ perception and requires cautious consideration by investors.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology to Review Interim Results and Dividend

Jinhai Medical Technology Limited has announced that its board of directors will convene on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting will also consider the payment of an interim dividend, which could have implications for shareholders and reflect the company’s financial health and strategic direction.

Jinhai Medical Completes Share Subscription, Eyes Expansion

Jinhai Medical Technology Limited has successfully completed the issuance of 120,000,000 new shares under its general mandate, raising approximately HK$161.0 million in net proceeds. The funds will be used for potential mergers and acquisitions in the healthcare sector, research and development, and general working capital. This strategic move slightly dilutes existing shareholders but positions the company for growth and expansion in its industry.